Evercore ISI Increases Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $280.00

Ascendis Pharma A/S (NASDAQ:ASND) had its price objective hoisted by analysts at Evercore ISI from $260.00 to $280.00 in a research report issued on Friday,Benzinga reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Evercore ISI’s target price points to a potential upside of 62.73% from the stock’s previous close.

A number of other brokerages also recently commented on ASND. Royal Bank of Canada began coverage on shares of Ascendis Pharma A/S in a research report on Wednesday, April 16th. They set an “outperform” rating and a $205.00 price objective on the stock. JPMorgan Chase & Co. upped their price target on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 18th. UBS Group assumed coverage on Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a “buy” rating and a $196.00 price objective for the company. The Goldman Sachs Group upped their target price on Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Finally, Morgan Stanley set a $180.00 price target on Ascendis Pharma A/S in a report on Tuesday, February 18th. Two investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $211.40.

Ascendis Pharma A/S Stock Performance

NASDAQ ASND opened at $172.06 on Friday. The firm’s 50 day moving average price is $155.31 and its two-hundred day moving average price is $140.33. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $183.00. The stock has a market cap of $10.49 billion, a price-to-earnings ratio of -24.23 and a beta of 0.41.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The company had revenue of $123.97 million during the quarter, compared to analysts’ expectations of $98.56 million. On average, research analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Institutional Trading of Ascendis Pharma A/S

Several large investors have recently modified their holdings of ASND. RA Capital Management L.P. raised its holdings in Ascendis Pharma A/S by 4.1% in the 4th quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company’s stock worth $1,392,221,000 after acquiring an additional 402,316 shares during the period. Avoro Capital Advisors LLC grew its position in shares of Ascendis Pharma A/S by 2.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 5,103,055 shares of the biotechnology company’s stock valued at $702,538,000 after purchasing an additional 114,167 shares during the last quarter. Artisan Partners Limited Partnership increased its stake in shares of Ascendis Pharma A/S by 0.9% in the fourth quarter. Artisan Partners Limited Partnership now owns 4,450,420 shares of the biotechnology company’s stock worth $612,689,000 after purchasing an additional 39,309 shares during the period. Janus Henderson Group PLC lifted its position in shares of Ascendis Pharma A/S by 4.6% during the 4th quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company’s stock worth $602,910,000 after purchasing an additional 193,688 shares during the last quarter. Finally, Capital International Investors boosted its stake in Ascendis Pharma A/S by 35.7% during the 4th quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company’s stock valued at $394,183,000 after purchasing an additional 753,859 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.